{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-009787","form_type":"8-K","ticker":"OTLC","cik":"0000908259","company_name":"Oncotelic Therapeutics, Inc.","filed_at":"2022-04-13T23:59:59+00:00","discovered_at":"2026-05-14T18:04:04.270044+00:00","generated_at":"2026-06-26T07:48:13.428152+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Oncotelic forms JV with Dragon Overseas for TGF-beta drug OT-101; Dragon invests ~$27.6M for 55% stake","bullets":["Oncotelic contributed global, exclusive, perpetual, royalty-free license of OT-101 IP for 45% ownership in JV.","Dragon Overseas invested ~$27.6M in cash and assets for 55% ownership of the JV.","JV to develop OT-101 for DIPG, pancreatic cancer, glioblastoma; company retains up to $50M from RPD voucher sale.","Oncotelic intends to pursue IPO of JV, citing recent successful TGF-beta IPOs.","JV will assume development costs; Oncotelic will participate via JV equity and voucher proceeds."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-009787","json":"https://secwatch.observer/filing/0001493152-22-009787.json","markdown":"https://secwatch.observer/filing/0001493152-22-009787.md","text":"https://secwatch.observer/filing/0001493152-22-009787.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/908259/000149315222009787/0001493152-22-009787-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/908259/000149315222009787/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T07:48:13.428152+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}